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Abstract 
 
Biomineralization is the process by which living organisms synthesize minerals. Some bone-
related proteins, such as bone sialoprotein (BSP), have been found to enhance biomineralization, 
while others, including osteopontin (OPN), act as inhibitors of this process. Dynamic light 
scattering was used to investigate the effect of several native and recombinant proteins and 
peptides on the formation and growth of hydroxyapatite (HA) crystals from solutions of Ca
2+
 and 
PO4
3-
 ions. We studied two isoforms of OPN, the OPN-derived peptides P0, P3, OPAR and 
pOPAR, and recombinant BSP. X-ray diffraction was used to identify the precipitate as HA 
crystals. Native OPN inhibits the nucleation of HA crystals, while recombinant OPN strongly 
inhibits their growth. Among the peptides studied, the non-phosphorylated P0 weakly inhibits 
HA growth, while P3, which has three phosphates, is a potent inhibitor of HA nucleation. OPAR 
is found to moderately inhibit nucleation, while its phosphorylated isoform pOPAR more 
strongly inhibits the nucleation of the HA crystals as well as having a small effect on their 
growth. This work confirms that phosphorylation of OPN is essential to its capability to prevent 
mineral growth. Our results show that for high enough ion and protein concentrations, rBSP 
inhibits the nucleation of HA, while there is some evidence that it enhances nucleation at very 
low protein concentrations 
.
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Chapter 1: Introduction and Literature Review 
 
1.1 Biomineralization 
 
Living organisms are capable of controlling the nucleation, growth and morphology of inorganic 
crystals within mineralized tissue. This process is called biomineralization. The geological 
record indicates that biomineralization has existed in some form for 3.5 billion years and that 
skeletal development first took place during Cambrian explosion [1]. Biomineralization occurs 
not only in the five animal kingdoms [2] but also in many plant species. Mollusk shells consist of 
two kinds of calcium carbonate (CaCO3), argonite and calcite [3]. Hydroxyapatite 
(Ca10(PO4)6(OH)2) is the major mineral component of mammalian bones and teeth and it makes 
up approximately 65% of their structure by weight [4], while plants are able to synthesize 
minerals such as calcium oxalate (CaC2O4) within their roots, leaves, stems and flowers as well 
as in fruits and seeds [5,6,7]. 
Minerals that have been made biologically contain organic as well as mineral components. They 
are produced under unusual conditions that are far from equilibrium, so the size, shape and 
crystallinity of biominerals are often very different from those of equivalent minerals formed by 
abiotic processes [5,8].  
Precise biochemical balancing of the biomineralization mechanism by protein inhibitors or 
nucleators is needed to prevent ectopic calcification or undesired mineral formation in soft 
tissues. Biological fluids like blood and urine are supersaturated with a variety of mineral salts, 
but regulatory proteins and low molecular weight inhibitors like citrate and pyrophosphate are 
responsible for preventing the minerals from coming out of solution [9]. A deficiency of the 
appropriate inhibitors of biominerals can lead to precipitation, resulting in pathological 
deposition such as arterial plaque and kidney stone [10]. 
Bone is a type of rigid connective tissue which serves to provide mechanical support for the body 
and to protect some organs, including the brain and spinal cord. Bone plays a role in the 
regulation of Ca
2+
 and PO4
3-
 ions in the body because it is a reservoir of these ions [11]. Cells in 
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the bone, including osteoblasts, osteocytes and osteoclasts have responsibility for remodeling the 
extracellular matrix (ECM), which provides structural support and is important for maintaining 
bone health. The organic extracellular matrix of bone consists of 90% type I collagen, while the 
remainder is non-collagenous proteins such as bone sialoprotein (BSP) and osteopontin (OPN). 
Type I collagen acts as a scaffold for the tissue, whereas the non-collagenous proteins, including 
the members of the SIBLING family of proteins discussed in Section 1.3, are responsible for the 
modulation of crystal nucleation, growth and orientation [12]. Hydroxyapatite that is formed on 
this scaffold is oriented along the long axis of the collagen fibers. It exists in bone and teeth as 
well as in pathological calcifications such as kidney stones and arterial plaque. Abiotic 
hydroxyapatite can be found in the form of a monoclinic crystal prism and hexagonal crystals at 
temperatures below and above 250°C respectively, while biological HA forms hexagonal crystals 
[13]. 
 
1.2 Crystal Nucleation and Growth 
 
Many biomineral products precipitate from an initial solution phase and are either completely 
crystalline or include crystalline components, so an understanding of the physical principles of 
crystallization from solutions is important. 
 
1.2.1 Nucleation 
 
The process by which a crystalline phase first develops in a saturated solution is termed 
nucleation. Nucleation happens via the formation of small crystal nuclei in the large volume of 
the solution. The solution is metastable, which means that the formation of crystals involves 
passage over a free energy barrier. Nucleation of crystals from solution can occur by two 
processes: heterogeneous nucleation and homogeneous nucleation. The former happens in the 
presence of a foreign substrate or surface that reduces the energy barrier. The formation of 
biominerals mostly begins by heterogeneous nucleation. In homogeneous nucleation, on the 
other hand, crystal nuclei spontaneously form in the absence of any impurities [14]. 
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When a solution of ions is supersaturated, ionic clusters of a critical size can form spontaneously 
and homogeneous nucleation occurs. The surface free energy of the solid-liquid interface, 
         , and the energy released by the formation of bonds within the cluster,       , 
determine the total free energy of nucleation associated with the formation of the cluster. The 
total change in free energy associated with the formation of the crystal is 
 
                        (1.1) 
 
where           and        are given by 
 
              
    (1.2) 
 
and 
 
 
       
       
   
   (1.3) 
 
In the above equations, r is the radius of the cluster, σ the free energy per unit surface area, Δu 
the molar energy of crystallization and Vm the molar volume. 
Combining Equations (1.1), (1.2) and (1.3) gives 
 
 
       
   
      
   
   (1.4) 
 
The surface free energy scales as r
2
 while the drop in bulk free energy scales as r
3
. This means 
that for a small radius cluster, the increase in           is larger than the drop in       , which 
results in the energy barrier described previously. The relationship between the radius of the 
cluster and its free energy of nucleation is illustrated in Figure 1.1. 
The difference between the free energy per molecule of the bulk and that of the surface is 
referred to as the interfacial free energy per molecule. The interfacial free energy acts to 
destabilize the nucleus, when the radius is smaller than a critical size r*, i.e. when the increase in 
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surface energy associated with increasing the size of the nucleus is larger than the decrease in 
bulk free energy, the nucleus is unstable. Typically, such a nucleus will dissolve rather than 
grow. As soon as the nucleus gets large enough, however, the decrease in free energy associated 
with the formation of the bulk phase becomes high enough that it dominates the increase in the 
surface free energy, and increasing the size of nucleus decreases the free total energy of the 
system. At the critical size r*, the free energy of the system is decreased whether the nucleus 
grows or dissolves [14]. 
 
 
Figure 1. 1: Gibbs Free Energy of Ionic Clusters. 
 
As shown in Figure 1.1, the free energy has a maximum at radius r*. This critical radius can be 
found by taking the derivative of     with respect to r and setting it equal to zero. The result is 
 
 
   
     
  
   (1.5) 
 
The formation of clusters with radii below the critical radius r* is energetically unfavorable and 
they will dissolve back into the solution. Increasing the concentration of the solution results in a 
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larger number of collisions among particles and hence the clusters which spontaneously form 
become larger in size. When the size of a cluster exceeds the critical radius, it will continue to 
grow, since its free energy decreases for increasing r. The crystal nucleus is now stable. 
The maximum value of the free energy of nucleation    
  at the critical radius is 
 
 
   
  
       
 
      
   (1.6) 
 
   
  is a measure of the activation energy for nucleation and is related to the rate of nucleation 
   by 
 
 
        (
    
 
   
)   (1.7) 
 
Here A is a constant,    is the Boltzmann constant and T is the temperature [14,15]. 
 
1.2.2 Heterogeneous Matrix-Mediated Nucleation 
 
One type of heterogeneous nucleation is matrix-mediated crystal nucleation. In this process, 
interactions between the protein matrix and the ions lower the potential barrier for the formation 
of critical nuclei. The exact process of this mechanism is not yet fully understood [12,16], but 
one postulated mechanism for matrix-mediated crystal nucleation and growth is illustrated in 
Figure 1.2. A high-resolution electron microscopy study of the growth of bone minerals showed 
that the process of crystal nucleation and growth has four stages [17]. In the first step 
(Figure 1.2 (a)), ions are absorbed on the organic matrix scaffold. The second step 
(Figure 1.2 (b)) involves the formation of crystal nuclei from the ions, leading to crystal growth 
(step 3, Figure 1.2 (c)). Step four (Figure 1.2 (d)) is fusion of crystals. This process is extremely 
sensitive to local variations in structure. 
In all biomineralization processes, the chemistry of the organic matrix plays a crucial role in the 
formation and growth of crystals. This chemistry depends on the amino acid sequence and/or 
post-translational modifications of proteins in the matrix. Proteins which have been suggested to 
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act as modulators of crystal formation or growth tend to be highly acidic or contain long 
sequences rich in acidic amino acids and phosphate groups [18]. Some of these proteins, such as 
bone sialoprotein (BSP), have been found to enhance the process, while others, including 
osteopontin (OPN), serve as inhibitors of biomineralization [19,20]. 
 
 
Figure 1. 2: Bone crystal growth mechanism a) ionic adsorption, b) nucleation, c) crystal growth, d) crystal 
fusion (adapted from [17]). 
 
1.2.3 Growth 
 
After a stable nucleus forms, it will be free to grow. What is necessary for a crystal to grow is 
that more ions bind to its surface than leave it. Binding tends to take place at specific sites on the 
surface [14,21]. Steps on the surface of the crystal separate flat terraces at different levels. As 
illustrated in Figure 1.3, steps at different positions can be connected by kinks. A molecule 
coming out of the solution makes more bonds to neighboring molecules when it attaches to a 
kink or at step edges than it does on the flat terraces. Kinks are thus key players in crystal 
growth. The rate of the crystal growth scales with the kink density, because the probability of the 
molecules leaving the crystal and returning to the solution from the kinks is much less than from 
7 
 
a complete step edge or a site on the terraces. This implies that the growth rate of a crystal can be 
reduced by preventing incoming molecules from reaching kink sites, or increased by roughening 
the crystal surface. 
 
 
Figure 1. 3: Illustration of a kink and a step on a crystal surface. Solute molecules bind at kinks either 
directly from solution or after adsorbing and diffusing across terraces. 
 
Organisms are able to control the location and crystallographic orientation of nucleation and the 
shape of the growing crystallites. The fact that certain organic compounds are found associated 
with biomineralized structures and their observed effect on crystallization kinetics indicate that 
these compounds modify the growth stage of minerals in addition to controlling nucleation. In 
fact, the complex crystal composites and the particular crystallographic orientations that are 
observed cannot be explained without appealing to some form of active control [14]. 
One of the most remarkable examples of biomineral growth is bone. It is believed that collagen 
fibers pack into periodic structures containing rows of small gaps known as "hole zones" 40 nm 
in length and 5 nm in width, as illustrated schematically in Figure 1.4. When certain proteins 
interact with this structural framework they induce nucleation of mineral within these gaps, while 
other proteins regulate the mineral growth process. As the nucleated mineral grows, it expands 
beyond the hole zones and develops into plates which enclose the collagen [14].  
Collagen itself is believed to have no effect on the nucleation of hydroxyapatite. In contrast, 
some noncollagenous proteins found in the organic part of the bone have been shown to bind to 
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HA crystals and influence their growth in vitro [4]. In particular, extracellular matrix 
phosphoproteins, which are acidic proteins containing phosphate groups, are known to be 
involved in triggering and controlling the growth of HA [20, 22]. 
 
 
Figure 1. 4: A schematic diagram of collagen matrix undergoing mineralization. The hole zones between 
collagen molecules act as nucleation sites for HA formation. 
 
The role and action of inhibitory molecules in the biomineralization process is an active area of 
research. Molecules like osteopontin [23-25] and Matrix Gla Protein (MGP) [26-28] have been 
demonstrated to inhibit both physiological and pathological HA formation and to affect crystal 
growth. One possible inhibition mechanism involves the protein binding to an existing crystal 
surface to inhibit the further deposition of ions. Another involves preventing the formation of 
critical nuclei by binding to and isolating free calcium. In the latter case the inhibitor decreases 
the number of nuclei available to grow rather than slowing their subsequent growth [12]. 
 
1.3 Proteins 
 
Proteins are large biological molecules consisting of one or more amino acid chains. After 
synthesis of the primary sequence, many proteins are modified by the addition of various groups 
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including sugars, phosphates, sulphates, and others. This process, termed post-translational 
modification (PTM), is essential for the functional attributes of many proteins including the 
proteins that are part of the SIBLING (Small Integrin-Binding LIgand, N-linked Glycoprotein) 
family of proteins.  Phosphorylation is a major PTM within this family. The SIBLINGs are 
major components of the extracellular matrix of bone and dentin, and have important roles in the 
mineralization of these tissues. Members of this family include osteopontin (OPN), bone 
sialoprotein (BSP), dentin matrix protein 1 (DMP1), dentin sialophosphoprotein (DSPP), and 
matrix extracellular phosphoglycoprotein (MEPE).  Phosphorylation of OPN is required for its 
mineral inhibition capabilities [29,30]. 
 
1.3.1 Osteopontin 
 
Osteopontin (OPN) is a highly post-translationally modified phosphoprotein. It has 
approximately 300 amino acid residues, and its average molecular mass is approximately 44 kDa 
[31]. Since it has a high content of aspartic acid and glutamic acid residues, including a 
contiguous aspartic acid sequence, it is strongly negatively charged. The negative charge density 
is increased by the post-translational modifications [32]. OPN is one of the most abundant non-
collagenous proteins, and is present in all body fluids as well as in a range of tissues including 
bone, kidney, lung and uterus. It is involved in a number of physiological processes in addition 
to biomineralization, such as cancer metastasis and wound healing [33-35]. Figure 1.5 gives the 
amino acid sequence of rat OPN [36]. In this figure, each letter refers to an amino acid. The 
twenty essential amino acids are shown in appendix A. 
Data from in vitro experiments support the notion that OPN inhibits HA crystal formation, 
although its structure is similar to BSP [24]. OPN is abundant in highly supersaturated 
physiological fluids and pathological depositions. For instance, it is the main organic constituent 
of calcium-oxalate-containing kidney stones [24,32]. OPN is not normally present in blood 
vessels, but is expressed in atherosclerotic plaque. It has been shown that OPN is expressed by 
soft tissues to prevent dystrophic calcification [24,37]. 
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Figure 1. 5Amino acid sequence of OPN including the 16 residue signal peptide. Each letter refers to an 
amino acid and the numbers in the parenthesis are the position of the residue in the complete amino acid 
sequence [36]. 
 
In vitro studies have indicated that native OPN, phosphorylated OPN-derived peptides, and 
synthetic OPN peptides are strong inhibitors of nucleation [23,24,38,40] and growth [39,40] of 
HA crystals. Although the mechanism by which mineral formation and growth are inhibited is 
poorly understood, other studies have shown that OPN also inhibits the formation of other 
biominerals, such as calcium carbonate [37] and calcium oxalate [41,42]. Hunter and co-workers 
found that modification of the glutamic acid and aspartic acid residues reduces OPN's inhibitory 
potency on HA formation [38]. Constant composition studies indicate that aspartic acid is a more 
effective inhibitor than glutamic acid [38]. It has also been demonstrated that the contiguous 
aspartic acid segment of OPN participates in preventing HA crystal growth [20,43]. 
Modulators of crystal nucleation and growth often have altered activities upon immobilization. 
For instance, OPN is a known inhibitor of HA formation in solution [22,23,38], but when 
immobilized can induce mineral formation [44]. Phosphorylation plays a key role in OPN's 
mineral-modulating activity, with phosphorylated OPN or its related peptides being much more 
inhibitory than the non-phosphorylated recombinant peptides [38,45,46]. It has been reported 
that the inhibitory potency depends on acidic regions rather than particular chemical groups 
[24,39]. 
de Bruyn et al. applied dynamic light scattering to characterize the mechanism of modulation of 
crystal formation. Their investigation showed that both nOPN and p-rOPN, a phosphorylated 
version of rOPN, inhibit the nucleation of particles from supersaturated calcium phosphate 
11 
 
solution. On the other hand, rOPN, which lacks the phosphorylations of nOPN, acted as an 
inhibitor of HA growth but not the nucleation [75]. 
Molecular dynamics simulations have helped elucidate the inhibition mechanism. Grohe et al. 
[30] found that phosphate groups had a significant role in bringing the peptide close to the crystal 
surface. They simulated three forms of the same OPN peptide (P0, P1, P3), which have the same 
amino acid sequence but different numbers of phosphorylations, interacting with a calcium 
oxalate monohydrate crystal. Another group performed simulations on phosphorylated OPN 
peptides in the presence of calcium oxalate, and also concluded that phosphate groups are 
involved in the inhibition of crystal growth [46]. 
 
Table 1. 1: Sequences of OPN-derived peptides used in this work. 
Peptide Name Amino acid # Sequence 
Molecular Weight 
(g/mol) 
P0 220-235 SHESTEQSDAIDSAEK 1733.7 
P3 220-235 pSHEpSTEQSDAIDpSAEK 1972.64 
OPAR (osteopontin 
poly-aspartate 
region) 
65-80 SHDHMDDDDDDDDDGD 1833.60 
pOPAR 65-80 pSHDHMDDDDDDDDDGD 1913.58 
 
Although phosphorylation of OPN seems to be essential to its capability to prevent mineral 
growth, it is not clear whether phosphorylation at particular sites in the protein is needed. In this 
thesis, we address this issue by testing some peptides for their effect on HA formation and 
growth using dynamic light scattering. The peptides listed in Table 1.1 were studied. P0 and P3 
corresponded to amino acids 220-235 of the native OPN protein, or residue 236-251 of the OPN 
sequence that includes the N-terminal signal peptide (Figure 1.5). P0 has no phosphorylations 
while P3 has three. Similarly, OPAR and pOPAR, while correspond to amino acids 65-80 of the 
native OPN protein, were studied. OPAR has no phosphorylations while pOPAR has one. 
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1.3.2 Bone sialoportein 
 
BSP is an acidic phosphoprotein which has been shown to be a nucleator of hydroxyapatite 
in vitro and capable of binding type I collagen [47,48]. Nucleation activity of BSP was first 
shown by Hunter and Goldberg in 1993 [20] in steady-state double-diffusion experiments using 
agarose gels. At concentrations of 5.5 mM Ca
+2
 and PO4
-3
, no precipitation occurred in the gels 
unless BSP was included. X-ray diffraction revealed that the recovered precipitates were HA. 
  
 
Figure 1. 6: Rat BSP amino acid sequence (adopted from [50]). The amino acid number refers to the position 
of the residue in the complete amino acid sequence, 1→ ←1 and 2→ ←2 refer to the first and second poly-
glutamic acid sequences. 
 
Physiological expression of BSP is essentially restricted to mineralized tissues such as bone, 
cementum (the calcified substance covering the root of a tooth), dentin and enamel [49]. 
Mammalian BSPs contain approximately 314 amino acids, including a 16-residue signal 
sequence [47,50]. Figure 1.6 illustrates the amino acid sequence of rat BSP. The molecular 
weight of mature BSP extracted from rat bone is 52.5 kDa [51], but there is much variability in 
this weight as BSP undergoes a number of heterogeneous post-translational modifications. 
Electron microscopy has shown that BSP has a rod-shaped core with an average length of 40 nm 
[52]. BSP expression is upregulated at times of first mineral deposition in mineralized tissues.  
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Its expression is also associated with pathological calcification. BSP expression has been 
observed in breast cancer [53], prostate cancer [54], lung cancer [55] and thyroid cancer [56], 
and it has been noted that BSP expression leads to the formation of HA crystals in carcinogenic 
tumors of the breast and increased metastasis of the cancer cells to bone [53].  
As discussed above, BSP is a modulator of mineral formation in steady-state agarose gels 
[20,22]. Analysis of the effect of BSP on HA formation indicated that this activity is associated 
with two regions of the protein, each of which consists of a sequence of contiguous poly-
glutamic acid residues [50,57]. While one domain is more effective than the other, neither is as 
potent as the full molecule [58]. BSP also contains several phosphates, which are found mainly 
on serine residues. A high proportion of Glu residues (approximately 22% of total amino acids) 
plus sulfate and phosphate groups make BSP highly acidic. The phosphorylations play a role in 
BSP's ability to nucleate crystal formation, though BSP without PTMs can still promote crystal 
formation [50].  
Fisher in 2001 [59], Wuttke in 2001 [60], and Tye in 2003 [50] showed by NMR (nuclear 
magnetic resonance), circular dichroism and small angle x-ray scattering respectively that BSP 
has a loose, flexible structure. In contrast, many other proteins have a stable three-dimensional 
structure. The unstructured nature of BSP likely allows BSP to interact with multiple partners 
including HA [48], collagen [61], matrix metalloproteins-2 [62] and Factor H [63]. BSP also 
contains an integrin-recognition sequence Arg-Gly-Asp (RGD) located near the carboxy-
terminal end of the molecule [57]. The RGD sequence promotes cell attachment, mediates cell 
signaling and has been shown to promote osteoprogenitor cell differentiation into osteoblasts 
[20,64]. 
Molecular dynamics (MD) is a powerful computer-based technique for predicting the 
interactions between small molecules at the atomic scale. Since crystals have a repeating 3D 
lattice, the interaction between peptides and crystal faces can be studied using MD simulations. 
Baht et al. performed MD simulations to investigate the nucleation mechanism of BSP [65]. 
Bone sialoprotein has two glutamic-acid-rich domains located at residues 42–100 and 133–205. 
Baht et al. simulated the regions BSP-(59–74) and BSP-(133–148) interacting with the {100} 
crystal face of HA. They found that for phosphorylated BSP-(133–148) every other glutamic 
acid is able to interact with the surface of the hydroxyapatite crystal to form an electrostatic 
14 
 
bond. This binding was less pronounced for non-phosphorylated BSP-(133–148). The 
phosphorylated peptide contained a longer, more-extended alternating pattern of bonds. This 
difference may explain why nucleation activity is enhanced in the phosphorylated form of the 
peptide [65]. Previous work by Tye et al. has shown that rBSP-(42-100), which also contains a 
Glu-rich region, does not nucleate HA [50]. Simulations of rBSP-(59-74) revealed that, despite 
having sites of phosphorylation, this peptide presented quite a different spatial distribution of 
side chains and did not adopt the pronounced alternating structure [65]. This suggests that a 
particular sequence of amino acids, in this case poly-Glu, is not the only factor that determines 
the nucleation potency of the peptide, and that the peptide structure is also important. On the 
other hand, Yang et al. also explored the possible role of BSP in nucleation of HA by molecular 
dynamic simulations [66]. Their results indicated that the sequence of poly-Glu residues plays a 
key role in the nucleation of amorphous calcium phosphate clusters which develop into 
crystalline hydroxyapatite. 
Mice lacking BSP are viable and breed normally, but there is a significant bone phenotype in 
young animals. It has been noted that there is a decrease in mineralization of cortical bones (the 
outer shell of the bone which is dense and contributes about 80% of the human skeleton) and 
shortened long bones for 0-4 months mice lacking BSP; however, this is overcome by the time 
the animals are 12 months old [67]. 
In 1996 Hunter et al. reported that in solution studies, BSP at concentration up to 10 μg/ml had 
no effect on hydroxyapatite formation [22]. An inhibitory effect of BSP and its peptides on 
crystal growth in a system of seeded HA crystals was observed by Stubbs et al. [68]. 
 
1.4 Methods for Characterization of Protein Modulation of Mineralization 
 
1.4.1 Steady State 
 
The effectiveness of crystal nucleator and inhibitor proteins is generally assessed using the 
steady state method. This makes use of a number of plastic cells containing agarose gels which 
are arranged in parallel. Calcium and phosphate solutions are separately pumped into the cells, as 
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illustrated in Figure 1.7. Spent solutions are collected in a reservoir connected to the outlet of the 
cell. A dialysis membrane separates both solution paths from the agarose gel in the center of the 
cell. Ions can diffuse across the membrane into the gel, forming a concentration gradient in the 
gel. Protein is premixed with the agarose in solution so it is evenly distributed and the agarose is 
then allowed to gel. The effect of the protein on nucleation can be assessed by observing the 
protein concentrations at which nucleation of hydroxyapatite takes place. Control experiments 
are conducted with no protein present. At the end of the experiment, the gels are examined to 
determine the calcium and phosphate content [20]. Although this technique has been used to 
determine the nucleation potency of a number of proteins including BSP, BSP-derived peptides, 
and other bone-related proteins, it has two major disadvantages. The method is very time-
consuming and requires at least five days to run a single experiment. In addition, it cannot be 
used to study the kinetics of the nucleation and growth process, but can only reveal whether or 
not mineralization has occurred. 
 
 
Figure 1. 7: Steady-state agarose gel system [adapted from 20]. 
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1.4.2 Constant Composition Method 
 
Another commonly used method of assessing the modulating potency of proteins and peptides is 
the constant composition method, which examines the effect of proteins on the growth of pre-
seeded HA crystals placed in a solution of calcium and phosphate ions [39]. Figure 1.8 illustrates 
this method. Seed crystals are added to a continually mixed, metastable solution of calcium and 
phosphate ions at pH 7.40. As the crystal grows, OH
-
 ions are used up, reducing the pH of the 
solution. This causes more calcium, phosphate, and sodium hydroxide to be released into the 
solution by an autotitrator to maintain the pH at the desired value. This feedback loop ensures 
that the composition of the calcium phosphate solution remains unchanged over the course of the 
experiment. Dissolution of carbon dioxide in the solution is prevented by bubbling nitrogen gas 
through it. The total amount of calcium released by the autotitration system yields a 
measurement of the crystal growth and can thus be used to generate titration curves. 
 
 
Figure 1. 8: Constant composition system. 
 
When inhibitor proteins are added to the calcium phosphate solution, the consequent decrease in 
the growth rate of the crystal is revealed through a lower volume of titrant added to the solution. 
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Comparison of the growth rate in the presence of the inhibitor at different concentrations with 
the results of the control experiment yields the protein's inhibition potency. The constant 
composition method is an accurate technique for the measurement of the effect of inhibitors on 
crystal growth and has been used to characterize proteins such as OPN [39]. This method is 
technically difficult and time consuming and, since it uses seed crystals, it gives no information 
on the effects of the protein on nucleation. 
 
1.4.3 Dynamic Light Scattering 
 
Light scattering is defined as the deflection of an incident beam of light by small particles. Lord 
Rayleigh pioneered the use of light scattering as a technique to study colloidal systems.  When 
radiation with a given wave vector is incident on a medium, some of it will be scattered by the 
medium. A detector positioned at an angle θ relative to the incident radiation will measure the 
intensity of the scattered radiation, I(θ,t). The scattering medium in our experiments is a 
suspension of small particles of precipitating calcium phosphate which over time will become 
HA. Since the scattering particles diffuse through the medium, I(θ,t) fluctuates over time. 
The scattering vector q is the difference between the propagation vectors of the scattered and 
incident beams. The magnitude of the scattering vector q is given by 
 
 
  
    
  
    (
 
 
)  (1.8) 
 
where n0 is the refractive index of the scattering medium and λ0 is the wavelength of the light in 
vacuum. 
The angular distribution of the intensity of light scattered from a colloidal suspension depends on 
the size of the suspended particles, the optical properties of the scatterers (such as their 
polarizability and refractive index) and the wavelength of the incident light. In a basic light 
scattering setup, one measures the average scattered intensity Is or the energy spectrum of the 
time dependent intensity, S(ω). Is contains information about the static properties of the scatterers 
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while S(ω) depends on their dynamics. Depending on which of these quantities is measured, 
therefore, light scattering experiments are generally classified as either static light scattering 
(SLS) or dynamic light scattering (DLS). In SLS, the average scattering intensity is measured as 
a function of scattering angle. Static light scattering measurements provide structural information 
about the scatterers such as molecular weight, radius of gyration, and shape as well as 
information about their spatial ordering [69].  
One useful and versatile technique to monitor the effect of proteins on the formation and growth 
of hydroxyapatite is DLS. In dynamic light scattering, one measures the time dependence of the 
scattered intensity. DLS can be used to acquire information about the effective hydrodynamic 
size of the suspended scatterers. Most previous studies of hydroxyapatite crystals growth have 
been carried out using constant composition seeded growth, but in 1998 Onuma et al. observed 
calcium-phosphate clusters with sizes around 1.0 nm in simulated body fluid using an intensity-
enhanced dynamic light scattering technique. Their report showed the stability of clusters over 
time. Their suggested model for cluster growth was that small calcium phosphate clusters packed 
together to form HA crystals [70]. 
The stable nanometer-sized calcium-phosphate clusters were detected in a solution containing 
these ions by DLS by Oyane and co-workers in 1999. They investigated the effect of 
concentration and pH of the solution on size distribution. They also showed that the 
concentration of clusters decreased when the supersaturation of the solution with respect to HA 
was decreased [71]. Omuna et al. also studied the precipitation kinetics of HA using a 
continuous-angle laser light scattering technique, and measured the molecular growth units of 
HA crystals [72]. 
Fibroblast growth factor-2 (FGF-2), is important in human hard tissue formation and has been 
studied by several groups. Onuma et al. adopted dynamic light scattering to monitor the size 
distribution of FGF-2 in solutions and the process of converting amorphous calcium phosphate to 
hydroxyapatite [73]. Kamiya et al. also used DLS to study the effect of lanthanum doping on the 
size distribution and growth of calcium carbonate crystals precipitating from solution. They 
found that the presence of La
3+
 ions caused the particles to grow slowly [74]. 
More recently de Bruyn et al. applied dynamic light scattering to characterize the mechanism of 
modulation of crystal formation. To evaluate the effect of PTMs, three isoforms of OPN – 
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nOPN, rOPN and p-rOPN – were examined. Their investigation showed that both nOPN and a 
phosphorylated version of rOPN, p-rOPN, inhibit the nucleation of particles from supersaturated 
calcium phosphate solution. On the other hand, rOPN, which lacks the phosphorylations of 
nOPN, acted as an inhibitor of HA growth but not the nucleation [75]. 
The effect of matrix gla protein (MGP) peptides on the in vitro formation of HA was also 
investigated by DLS by Goiko et al. [27]. MGP is a phosphorylated and γ-carboxylated protein 
which prevents the deposition of HA in the walls of blood vessels and kidney. To distinguish the 
effect of phosphorylation and γ-carboxylation on HA nucleation, MGP-derived peptides 
containing these modifications were compared to unmodified peptides. Their results indicated 
that the inhibitory effects on nucleation were dependent on these modifications, and that γ-
carboxylated groups, similar to phosphorylation, enhances inhibitory activity [27]. 
 
1.5 Purpose of this Thesis 
 
The details of the process of biomineralization are complex and not completely understood. It is 
known that certain proteins play key roles in both the initial nucleation of biomineral crystals, 
and in the regulation of their growth. Some have been observed to enhance nucleation and/or 
growth while others act as inhibitors. Controlled biomineralization is vital for mammalian life, 
and unregulated mineralization can lead to pathological deposition, causing serious medical 
diseases. There is, therefore, considerable motivation for characterizing and understanding the 
process of biomineralization, and in particular the role of protein on nucleation and growth 
regulation.  
This project began with the goal of studying the effect of BSP on both nucleation and inhibition. 
Previous work by Hunter et al. in 1993 [20] and Baht et al. in 2008 [47] demonstrated BSP-
mediated nucleation of HA using agarose and collagen gel-based systems, respectively. Dynamic 
light scattering provides an alternative method of investigating the kinetics of nucleation and 
growth of hydroxyapatite crystals in the presence of bone-related proteins or synthetic peptides. 
Based on our group's success at studying inhibition of mineral formation using dynamic light 
scattering [27,75], we initiated DLS studies to characterize early nucleation events mediated by 
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BSP. Such results would have provided valuable insight into the nucleation process in 
biomineralization. However, we had difficulty in finding the correct conditions to study 
nucleation, so this study evolved to focus on inhibition of mineral formation.  
The present work uses dynamic light scattering to characterize the inhibitory effects of BSP, 
OPN, and OPN-derived peptides on hydroxyapatite formation and growth. To examine the 
effects of phosphate groups, both phosphorylated (P3 and pOPAR) and non-phosphorylated (P0 
and OPAR) peptides were studied. The goal of this study is to help elucidate the process of 
biomineralization. Ultimately, understanding of this process could lead to the development of 
peptide therapies to control pathological calcifications that result from the breakdown of the 
body’s natural biomineralization regulatory system. 
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Chapter 2: Methods 
 
2.1 Dynamic Light Scattering 
 
2.1.1 Theory of Dynamic Light Scattering 
 
In dynamic light scattering, laser light is scattered by a collection of suspended particles, and the 
intensity of scattered light is measured at a particular angle with a photomultiplier detector 
(Figure 2.3). In a colloidal suspension, the motion of the particles is random and is due to 
Brownian motion. The total scattered electric field at the detector is the superposition of the 
scattered fields due to all of the particles. In the scattering volume, which is the volume that is 
both illuminated by the incident beam and observed by the detector [76], the positions of the 
particles vary in time, so the phase of each scattered wave arriving at the detector fluctuates in 
time, and E(t), the total scattered electric field at the detector, also fluctuates. This in turn causes 
fluctuations in the intensity, which is defined as 
 
               (2.1) 
 
where t is the time. These fluctuations in the scattered intensity are the key concept of DLS 
experiments. DLS involves measuring the fluctuations in the intensity of the scattered light and 
analyzing them to the extract information. The time scale of these fluctuations depends on the 
size of the diffusing particles [76], so they can be analysed to calculate the average size of a 
particle diffusing in solution. Small particles diffuse more quickly, and so cause a rapidly 
fluctuating signal, whereas larger particles diffuse more slowly, resulting in more slowly varying 
fluctuations. Figure 2.1 shows a schematic example of an intensity-time plot for small and large 
particles. 
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Figure 2. 1: Left: A schematic illustration of the fluctuations in scattered intensity observed for scattering 
from large and small size particles, Right: Correlation functions for large and small size particles. 
 
It should be emphasized that the fluctuations in the scattered intensity do not result from changes 
in the number of particles in the scattering volume, but from changes in the position of the 
scatterers. We can get quantitative information out of these fluctuations by examining the decay 
of their autocorrelation function. The intensity autocorrelation function      shows the 
correlation between scattered intensity at a given time t and a later time    . In order to get 
good statistics, this comparison is normally made at many different values of t and averaged. If 
one denotes the scattered intensity at an arbitrary time by      and that at a later time   by 
      , the autocorrelation function is 
 
      〈          〉  (2.2) 
 
Here, the angle bracket represents an average over time. When τ=0 the two signals are the same 
since the particles have not moved from their initial position and the correlation is high. If the 
sampling time interval   is very large, there is no correlation between the pairs of sample 
intensities and the above equation becomes 
 
      〈        〉  〈    〉   (2.3) 
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In our experiment, a digital correlator takes the digitized photo-count measured by the detector, 
which is proportional to     , and then computes the correlation function. This function then is 
normalized by the value of the correlation function at long times,     . The normalized 
correlation function of the scattered intensity is referred to as         and is given by 
 
 
        
〈          〉
〈    〉 
   (2.4) 
 
If the scattering is a Gaussian process,         is related to the autocorrelation function of the 
electric field,        , by the Siegert relation [77] 
 
 
           (       )
 
  (2.5) 
 
where   is a constant that depends on the size of the detector and the details of the optics of the 
experimental set up. If the particles are spherical, monodisperse, and undergo Brownian motion, 
the autocorrelation function of electric field,        , decays exponentially with delay time: 
 
                     (2.6) 
 
where D is the translational diffusion coefficient. One can find the hydrodynamic radius, which 
is the quantity of interest in the present work, from D using the Stokes-Einstein relation,  
 
 
   
   
    
   (2.7) 
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Here   is the Boltzmann constant,   is the absolute temperature, and   is the viscosity of the 
solution. If the scattering particles are not spherical, DLS measurements provide the apparent 
hydrodynamic radius of the particles being examined. If they are polydisperse,         can be 
expressed as an integral over a distribution of decay rates, from which the distribution of sizes 
can in principle be determined [69,77]. 
 
 
Figure 2. 2: A typical example of autocorrelation function for different-sized particles. The curves are fit to 
an exponential decay. The fitted values for the radii are a=2.5 nm, b=54 nm, c=214 nm and d=422 nm. [69]. 
 
Figure 2.2 depicts the dependence of the electric field correlation function,        , on time 
interval   for nanoparticle scatterers with different sizes. A line has been fitted to data by 
assuming a single exponential decay. From the figure we can infer that as the size of the particles 
becomes larger, the decay of the correlation function shifts to a longer time. The average 
hydrodynamic size of particles can be roughly evaluated by using this shift. 
In this thesis, the sample studied is a suspension of small calcium phosphate crystals 
precipitating from solution. Measurement of the intensity autocorrelation function as a function 
of time allows us to follow the changing hydrodynamic radius of the crystals as they grow. 
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Moreover, the average scattered light intensity can be computed as a function of time, allowing 
for at least a qualitative measure of the concentration of scatterers. As a result, DLS not only 
allows us to assess the effect of the proteins on the growth rate but also on the nucleation of 
hydroxyapatite crystals. 
 
2.1.2 Dynamic Light Scattering Experiment 
 
The effects of proteins on the nucleation and growth of crystals can be studied using dynamic 
light scattering (DLS). This technique is very effective for measuring the sizes of small particles 
as well as for studying protein-protein interactions. It has also been extensively used to examine 
the conditions that affect protein crystallization through assessing the sample homogeneity 
[70,78,79]. DLS has been used to study the full native and recombinant OPN protein [75], but it 
has not been used to study BSP. 
Our DLS experimental set-up is schematically depicted in Figure 2.3. The light source is a HeNe 
laser with a wavelength of 632.8 nm and power of 22 mW. A CGS-3 compact goniometer 
system manufactured by ALV-GmbH was used to perform the scattering measurements. A 
photomultiplier detector is positioned on one arm of the goniometer, and can be rotated to 
measure the scattered light intensity at angles ranging between 12° and 155°. The 
photomultiplier signal is passed to an amplifier, and the digitized output is received by a digital 
correlator which calculates the intensity autocorrelation function,        , in real time. The 
intensity autocorrelation function is then sent to a computer along with the intensity-time data. A 
MATLAB program written by Dr. de Bruyn, which will be discussed below, performs curve 
fitting on the autocorrelation function to determine the distribution of hydrodynamic radii of the 
scatterers. 
The experiments described in this thesis were all performed at a scattering angle of 90°. The 
samples were placed in a clean cylindrical cuvette with a radius of 5 mm and made of optical 
quality glass. The cuvette is positioned in a chamber at the center of a circular vat filled with 
toluene. Since the refractive index of toluene is close to that of the glass, this minimizes stray 
scattering from the surface of the cuvette. The temperature of the toluene bath was kept constant 
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at 25°C by a temperature controlled circulating bath. The measurements for a given 
concentration of protein or peptide were carried out over a 40 minute period. The intensity 
autocorrelation functions and mean scattered intensity were calculated from the accumulated 
data every 30 seconds. 
 
 
Figure 2. 3: The experimental set up of the light scattering instrument. 
 
2.1.3 Data Analysis 
 
Because of the random motion of the scattering particles, the autocorrelation function of 
scattered electric field,        , will decay as τ increases. The hydrodynamic radius of the 
scatterers, which is the radius of a sphere that would have the same average diffusion constant as 
the scattering particles, is calculated from its decay rate. For a system of monodisperse scatterers, 
        decays exponentially with delay time. In our experiment, we have polydisperse 
scatterers, so         will not have a simple exponential decay. As discussed in [70,77] the first 
two terms of a cumulant expansion for         are 
 
 
              ̅  (  
  
 
  )  (2.8) 
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where  ̅  is the mean relaxation rate of          , and    is its second moment. The electric 
field autocorrelation function         is related to         by Equation (2.5), which, using 
Equation (2.8) can be written as 
 
 
                        ̅  (  
  
 
  )  (2.9) 
 
Here the baseline, B, is approximately one, but varies due to noise. We determined  ̅ and    from 
the measured intensity autocorrelation function using a standard non-linear least-squares fitting 
routine. Once  ̅ and    were computed from the fits, the mean hydrodynamic radius,  ̅ , was 
calculated using Equations (2.6) and (2.7) as  
 
 
  ̅   
    
 
    ̅
   (2.10) 
 
We used        and                 , for the refractive index and viscosity of water at 
25°C. 
The standard deviation of the Gaussian size distribution is 
 
 
   √  
  ̅ 
 ̅
   (2.11) 
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2.2 Identification of Precipitates 
 
The crystals precipitated in our experiments were extracted from the solutions and identified by 
X-ray diffraction. Details of this technique and the method for harvesting the crystals are 
described in this section. 
2.2.1 X-ray crystallography 
 
X-ray crystallography is a powerful and non-destructive technique for determining the crystal 
structure of many kinds of materials, including solid crystals, powders, and biological 
macromolecules such as proteins.  
X-rays are electromagnetic radiation with energies above ultraviolet light and below gamma 
rays. The wavelengths of X-rays are in the range 0.1-100 Å and their energy is between 120 keV 
and 0.12 keV.  
 
2.2.2 X-ray diffraction from a crystal: Bragg’s Law 
 
A crystal is composed of periodic planes of atoms. The planes are indexed by a set of integers 
indicating their direction. Atoms in each plane scatter incident X-rays. If every atom scatters X-
rays as shown in Figure 2.4, then constructive interference will be observed at certain angles. 
The light waves constructively interfere when they are exactly in phase. Assuming that the 
incident waves 1 and 2 in Figure 2.4 are in phase when emitted from their source, then the 
condition for them to interfere constructively after scattering is that the additional distance 2x 
traveled by wave 2 is equal to an integer number of wavelengths. Since 
 
          (2.12) 
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where d is the distance between the planes and θ is the angle between the incident X-ray and the 
plane, a diffraction peak is observed when 
 
            (2.13) 
 
This equation is known as Bragg’s Law. As seen in Figure 2.4, the angle between the incident 
and diffracted beams is 2θ. Bragg’s law is derived assuming that the atoms are exactly above 
each other on the planes, but in fact, they can be located anywhere on the planes [80,81,90]. 
 
 
Figure 2. 4: X-rays scattering from two parallel planes. S0 indicates the incident X-ray beam and S1 the 
diffracted beam [81]. 
 
2.2.3 Crystal Preparation 
 
The amount of precipitate formed in one 1.8 ml sample tube is very small. Roughly 1 mg of the 
precipitate is needed for X-ray diffraction analysis, so several reaction mixtures in tubes were 
prepared in parallel to obtain sufficient material for analysis.  
The precipitation was allowed to take place for 40 minutes, the same length of time as the DLS 
experiments. The solutions from all of the test tubes were then transferred to microfuge tubes and 
centrifuged at 8000g for 2 minutes. The supernatant liquid was removed using a pipette, and the 
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crystals were washed with 100 μl or more pH10 water. pH10 water is a mixture of 10% 
ammonium hydroxide and deionized water and is used to stop the reaction between calcium and 
phosphate ions. The tubes were shaken gently to wash the crystals well and centrifuged again for 
2 minutes. The pH10 water was then removed and 100 μl or more 100% ethanol was added to 
the tubes. Once again, the microfuge tubes were gently tapped, and then all the contents were 
combined into a single tube and centrifuged for 2 minutes. The ethanol was removed and the 
collected precipitant dried at room temperature and stored in a dessicator. 
The precipitate was analyzed with a Bruker D8 Discover micro X-ray diffractometer using 
Cobalt Kα radiation (1.78897 Å) (performed by Prof. Roberta Flemming and Michael Bramble 
from Western’s Department of Earth Sciences). The crystal structure was identified by 
comparing the measured diffraction pattern with catalogued standard patterns from the 
International Centre for Diffraction Data (ICDD) database. 
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Chapter 3: Materials 
 
3.1 Preparation of Solutions 
 
A significant amount of time was spent to find the appropriate concentrations of reagents and 
preparation technique that resulted in reproducible results.  
For our studies of nucleation and inhibition, four 100 ml stock solutions of sodium chloride 
(NaCl), sodium phosphate dibasic (Na2HPO4), tris (hydroxymethyle) aminomethane 
(C4H11NO3), and calcium chloride (CaCl2) with concentrations of 2.0M, 0.25M, 1.0M, and 0.5M 
respectively, were prepared using deionized water. All of the chemicals were purchased form 
Sigma-Aldrich Inc and had purities of above 99%. To remove bacteria and minute particles, the 
solutions were filtered through 0.2 μm membrane filters (Nalgene). The stock solutions were 
kept in clean, autoclaved bottles. Stock solutions were normally made fresh every two weeks to 
ensure reproducible results.  
Three 50 ml working solutions were prepared daily from the stock solutions. The working 
solutions were: a calcium solution consisting of 12 mM CaCl2, 150 mM NaCl, 18.75 mM Tris; a 
phosphate solution containing 7.5 mM Na2HPO4, 150 mM NaCl, 18.75 Tris; and a Tris solution 
with 150 mM NaCl and 18.75 mM Tris. The pH for each solution was adjusted to 7.40 by adding 
dilute NaOH or HCl. This pH and the NaCl concentration were chosen to mimic in vivo 
conditions. Since any contaminants could scatter light and skew the results, the solutions were 
filtered a second time through fine 0.02 μm Whatman syringe filters directly into sterile BD 
falcon tubes. These final working solutions were only used on the day of preparation to ensure 
reproducible results. 
In order to find suitable control conditions for hydroxyapatite crystal formation and growth, we 
prepared and tested solutions with different concentrations of calcium and phosphate ions. The 
rate of crystal growth should be slow enough to allow time to perform a measurement, but fast 
enough that a significant change in the crystal size took place over the forty-minute duration of 
the experiment. The growth rate is very sensitive to small changes in pH and temperature, so we 
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had to slightly change the concentration of Ca
2+
 and PO4
3-
 for experiments performed on 
different days. Each day, the selected control concentrations of ions were then used for all 
experiments on that day. 
Tables 3.1 and 3.2 give the Ca
2+
 and PO4
3- 
concentrations and volumes that were used in each 
protein or peptide-containing run. All concentrations of a given protein or peptide were tested on 
the same day. For each run, the ratio of Ca
2+
 and PO4
3-
 was maintained at 1.60, which is the most 
favorable value for hydroxyapatite formation. 
 
Table 3. 1: The concentration and volume of Ca
2+
 and PO4
3-
 solutions used for protein runs. 
Protein [Ca
2+
] (mM) VCa (μl) [PO4
3-
] (mM) VPO4 (μl) 
nOPN 5.800 870 3.625 870 
rOPN 5.400 810 3.375 810 
rBSP 5.200 780 3.250 780 
rBSP 5.400 810 3.375 810 
 
Table 3. 2: The concentration and volume of Ca
2+
 and PO4
3-
 solutions used for peptide runs. 
Peptides [Ca
2+
] (mM) VCa (μl) [PO4
3-
] (mM) VPO4 (μl) 
P0 5.460 820 3.416 820 
P3 5.400 810 3.375 810 
OPAR 5.660 850 3.541 850 
pOPAR 5.730 860 3.583 860 
 
In all cases, a total volume of 1.8 ml was used. The volumes of calcium and phosphate solutions 
given in the Tables were combined with sufficient Tris solution to give the required total volume. 
When an aliquot of dissolved peptide in Tris buffer was added to the solution the volume of Tris 
solution was reduced accordingly. The required volume of calcium solution, Tris buffer and the 
protein or peptide under study were combined in a 5 ml borosilicate glass tube, and then the 
phosphate solution was added to initiate the nucleation of HA. The glass tube was gently 
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inverted three times to mix the solutions, and was then cleaned and immediately put in the 
sample chamber of the light scattering instrument. 
 
3.2 Proteins and Peptides Preparation 
 
To investigate the role of phosphorylation in biomineralization process, native and recombinant 
proteins and synthetic peptides containing 0, 1 and 3 phosphate groups were used. The proteins 
studied were native osteopontin (nOPN), recombinant osteopontin (rOPN) and recombinant bone 
sialoprotein (rBSP). These proteins were prepared in-house.  For example, nOPN was extracted 
from rat bone and then purified by H. Chen using the protocol described in [82]. Rat nOPN was 
shown to have a mass of 37600 g/mol, and contained approximately 10 phosphate residues per 
molecule. Furthermore it is glycosylated and sulfated [75]. Recombinant rat osteopontin, 
containing a short His-tag for purification purposes, was expressed by BL-21 bacteria and 
purified [32]. It has a mass of 36046 g/mol and contains the same polypeptide chain as nOPN but 
without the post-translational modifications. Similarly, rBSP was expressed and purified by 
H. Chen as described in [50]. One of the serine amino acid of the rBSP used in these studies was 
substituted by alanine. The rBSP has a molar mass of 34780 g/mol [12]. 
We also studied the peptides P0 and P3, which correspond to amino acids 220-235 
(SHESTEQSDAIDSAEK) of rat OPN and contain zero and three phosphates, respectively, and 
OPAR and pOPAR, which include amino acids 65-80 (SHDHMDDDDDDDDDGD) of rat bone 
OPN, and which contain zero and one phosphate, respectively. 
Phosphorylated and non-phosphorylated peptides were synthesized by a batch method and 
purified by Y. Liao as described in [29,30,39]. The final peptide preparations were >98% pure. 
The peptide masses were obtained using mass spectrometry and are presented in Table 1.1. 
All the proteins and peptides were stored at -20°C as pre-weighed freeze-dried aliquots. For the 
experiments one or more tubes of protein were dissolved into a volume of filtered 0.05 M Tris 
buffer solution at pH 7.4 to achieve a concentration of 1 μg/μl. The amount of protein solution 
used in individual experiments is indicated in the Results. To prevent degradation of the 
dissolved protein aliquots they were kept on ice until used. 
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Chapter 4: Results 
 
4.1 Dynamic Light Scattering Results for Control Experiments 
 
Prior to doing each set of experiments we carried out control experiments with no protein or 
peptide added to the calcium phosphate solution. The control experiments provide a baseline for 
the nucleation and growth of hydroxyapatite crystals in the absence of protein or peptide. They 
also help us to confirm the consistency of the results. Control solutions were prepared using the 
method described in section 3.1 and Table 3.1 and Table 3.2. The intensity autocorrelation 
function for one of the control experiments is plotted in Figure 4.1. The red line is a fit to 
Equation (2.9). 
 
 
Figure 4. 1: Intensity autocorrelation function for a typical control experiment. The fit to Equation (2.9) is 
shown as a red curve. 
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Having determined  ̅ from the fit, we can find the mean hydrodynamic radius from Equation 
(2.10) as described above. 
 
 
Figure 4. 2: A) The mean scattered light intensity,   , and B) the mean hydrodynamic radius of the particles, 
 ̅  in the absence of protein. 
 
Figure 4.2 (A) shows the time dependence of the averaged scattered light intensity,   , as well as 
the standard deviation of the fluctuating intensity for a typical control experiment. Note the mean 
value, Im, is much smaller than these error bars. The averaged scattered light intensity is given in 
terms of the photon count rate detected by the photo multiplier. During the first two minutes of 
the experiment, the data are not reliable because of fluid motion due to mixing and placing of the 
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sample in the chamber. Over the duration of the measurements, the scattered intensity increases 
steadily and relatively linearly as the calcium phosphate precipitates. The scattered light intensity 
depends in a complex way on the size of the scatterers as well as their concentration [75,76].  
For the range of particle sizes relevant here,      is approximately proportional to particle 
concentration and to   ̅
  [76,83]. Therefore, the size of the scatterers has more impact on      
than their concentration.  
The dependence of   ̅ on time for the same control run is shown in Figure 4.2 (B). In this Figure, 
the error bars, σr, represent the standard deviation of the Gaussian distribution of particle sizes 
obtained from the fit, as described in Equation (2.11). As above, the uncertainty on   ̅ is much 
smaller than these error bars. At the beginning of the experiment   ̅ is about 120 nm, and it 
grows to approximately 700 nm at forty minutes. The width of the size distribution is relatively 
broad and becomes larger as time passes. The growth rate of the precipitating particles is given 
by the slope of the plot of   ̅ versus time, and is higher at the beginning of the experiment than at 
the end. 
 
4.2  X-ray Diffraction Result for Control Experiments 
 
The protocol described in section 2.2.3 was used to recover crystals from a control experiment. 
The results of the X-ray diffraction analysis are shown in Figure 4.3. The diffraction pattern of 
the precipitate that formed in the control experiment matched well with the ICDD card # 01-073-
0293 for hydroxyapatite. The intensity of the Debye rings (results not shown here) is uniform, 
implying that the crystals are fine grained. The narrow diffraction lines, illustrated in Figure 4.3, 
demonstrate that the crystals are well-formed. From the width of the peaks the size of the crystals 
is estimated to be 200 nm. This is slightly less than the value of   ̅ measured with DLS. The red 
and green lines shown in the figure are expected diffraction peaks for hydroxyapatite and 
calcium phosphate hydrate respectively. The measured diffraction pattern is very similar to both, 
but calcium phosphate hydrate is not expected to form under the conditions in our experiments. 
Our crystals were therefore identified as hydroxyapatite. 
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Figure 4. 3: X-ray diffraction pattern of precipitate collected from a control experiment compared to 
standard spectra for hydroxyapatite (red) and calcium phosphate hydrate (green). 
 
4.3 Dynamic Light Scattering Results for nOPN 
 
We examined the effect of nOPN on HA crystal nucleation and growth. The prepared solution 
contained 5.80 mM calcium and 3.63 mM phosphate ions. Figure 4.4 (A) shows the scattered 
intensity as a function of time for concentrations of 0, 1, 2, 3, 4, and 8 μg/ml nOPN. These 
concentrations correspond to approximately 0.03, 0.06, 0.08, 0.12, and 0.24 μM of nOPN. Here, 
the error bars for the scattered intensity indicate the standard deviation of the count rate. Adding 
1 μg/ml nOPN notably decreases the scattered light intensity, and as the concentration of nOPN 
is increased, the scattered intensity drops further. From Figure 4.4 (B) we can see that the 
presence of nOPN causes a delay in nucleation and growth of the particles. The delay times 
become larger as the nOPN concentration increases. 
Figure 4.4 (B) shows the mean hydrodynamic radius as a function of time for different 
concentrations of nOPN. The error bars on the plot of  ̅  versus time indicate the standard 
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deviation of the distribution of the particle sizes, σr, which is found by fitting Equation (2.9) to 
the intensity autocorrelation function. At early times,   ̅ remains low and smaller than in the 
control experiment. After a delay, it finally starts to grow. Similar to what was observed for the 
scattered intensity, the presence of nOPN delays the growth of the particles, with the delay time 
becoming larger as the concentration increases. Once the crystals start to grow, they grow faster 
than in the control experiment, and eventually, the size of precipitating particles becomes larger 
than in the control experiment. In spite of this, the scattered intensity is always smaller than that 
of the control experiment. As described earlier, the scattered intensity depends on both the 
concentration and the size of the scatterers. Here, in the presence of nOPN, the size of the 
scattering particles increases but the scattered intensity remains lower than the control value. We 
can therefore infer that the concentration of the scattering particles decreases in the presence of 
nOPN. These results imply that nOPN inhibits the nucleation of the HA crystals. Very few 
calcium phosphate particles can nucleate when nOPN is added to the solution, but, as 
Figure 4.4 (B) shows, after a delay those particles grow faster in the presence of nOPN than in 
the control experiment. 
Figure 4.4 (C) shows the scattered light intensity as a function of hydrodynamic radius. At a 
fixed size of scatterers, Im depends only on the number of scattering particles. For sizes greater 
than about 200 nm, the number density of the scattering particles decreases significantly when 
protein is added to the solution. For instance, at 400 nm the value of Im for 1 μg/ml nOPN is 
smaller than the control value by a factor of five. Overall, the results suggest that nOPN inhibits 
the nucleation of HA crystals. 
The delay time was found by fitting a straight line to   ̅    in a time interval just after it starts to 
grow significantly and then extrapolating the fit to   ̅   . Figure 4.5 illustrates that the delay 
time increases with concentration of protein. The dashed line, which is a linear fit to the data 
points, implies that there is a threshold concentration of 0.65±0.47 μg/ml for nucleating HA 
crystals in presence of nOPN. 
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Figure 4. 4: (A) The mean scattered intensity versus time, (B) The mean hydrodynamic radius of the 
scatterers as a function of time, (C) The mean scattered photon count rate as a function of hydrodynamic 
radius in the presence of a range of concentration of nOPN added to the calcium phosphate solution. 
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Figure 4. 5: Delay time as function of nOPN concentration for the beginning of the crystal growth. 
 
4.4 Dynamic Light Scattering Results for rOPN 
 
We studied the effect of recombinant OPN on the nucleation and growth of hydroxyapatite. 
Since rOPN lacks the phosphorylations of the native OPN, comparison of the results of these 
experiments with those of section 4.3 should provide information on the role of those 
phosphorylations on control of biomineralization.  
Figure 4.6 (A) and (B) show the scattered photon count rate and the hydrodynamic radius of the 
scatterers in the presence of 1, 3, and 6 μg/ml rOPN. These concentrations correspond to 
approximately 0.03, 0.08, and 0.17 μM of rOPN. As in the case of nOPN,    decreases as the 
rOPN concentration increases but    ̅ behaves differently.   ̅ decreases as the concentration of 
rOPN increases with minimal apparent growth of particles at high concentrations. As the 
concentration increases from 1 μg/ml to 3 μg/ml the hydrodynamic radius drops significantly. At 
6 μg/ml rOPN, the highest concentration studied, the particles grow very little over the duration 
of the measurement. By the end of the experiment, there is a 94% decrease in the radius of the 
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scatterers in the presence of 6 μg/ml rOPN relative to the control measurement. Based on these 
observations, we can infer that rOPN strongly inhibits the growth of HA crystals. 
The scattered light intensity is plotted as a function of   ̅ in Figure 4.6 (C). At small   ̅,    is 
considerably higher in the presence of rOPN than in the control experiment. Thus, we can infer 
that at a fixed size of scatterers, the concentration of calcium phosphate particles is larger in the 
presence of the protein than in the control solution. 
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Figure 4. 6: Precipitation of calcium phosphate solution in the presence of recombinant OPN. (A) Mean 
scattered light intensity and (B) Mean hydrodynamic radius as a function of time for different concentration 
of rOPN. (C) Mean scattered light intensity as a function of hydrodynamic radiius. 
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4.5 X-ray Diffraction Results for nOPN and rOPN 
 
Crystals were also harvested from experiments performed with 1 µg/ml nOPN and 1 µg/ml 
rOPN. The measured X-ray patterns are shown in Figures 4.7 and 4.8, respectively. Both 
samples have diffraction pattern features that match hydroxyapatite, ICDD card # 01-073-0293. 
As in the control experiment, the crystals formed in the presence of the proteins were very fine 
grained, as evidenced by broadening of the Debye rings in the powder pattern. Comparison of 
the X-ray diffraction patterns of the precipitants formed in the presence of nOPN and rOPN with 
that from the control experiment indicates that the patterns are similar, so the crystals formed are 
the same in all cases. 
 
 
Figure 4. 7: X-ray diffraction pattern of precipitate collected from experiments in presence of 1 µg/ml nOPN. 
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Figure 4. 8: X-ray diffraction pattern of precipitate collected from experiments in presence of 1 µg/ml. 
 
4.6 Dynamic Light Scattering Results for P0 
 
In vivo and in vitro studies have shown that OPN inhibits the nucleation and growth of HA and 
other biominerals and prevents the calcification of soft tissues. However, the nature of the 
interaction between OPN and HA is not yet fully understood. We performed experiments on 
peptides derived from OPN to investigate the inhibitory effects of particular regions of the 
protein. P0 is a non-phosphorylated peptide corresponding to amino acids 220-235 from OPN. 
Aliquots of 5, 7, 10 and 15 μg/ml of P0 were added to a solution with ion concentrations of 
5.46 mM calcium and 3.41 mM phosphate. These peptide concentrations correspond to molar 
concentration of 3.0, 4.0, 6.0 and 9.0 μM, respectively. The results for P0 are presented in 
Figure 4.9.  
As can be observed in Figure 4.9 (A), increasing the concentration P0 has only a small effect on 
the scattered light intensity. For the highest concentration of P0, 15 μg/ml, the average scattered 
light intensity at the end of the experiment decreases by 22% relative to the control level. 
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Figure 4.9 (B) demonstrates that hydrodynamic radius measured at peptide concentrations of 5, 
7, and 10 μg/ml overlaps with the control data. Addition of 15 μg/ml of P0 to the solution causes 
the hydrodynamic radius to decrease slightly below the level of the control. These observations 
indicate that P0 has a very weak effect on HA formation, and inhibits crystal growth only at very 
high concentrations. Figure 4.9 (C) shows the intensity as a function of hydrodynamic radius. 
The scattered intensity at a given hydrodynamic radius in the presence of 5, 7, and 10 μg/ml 
peptide is slightly below the control experiment, indicating a small decrease in the concentrations 
of scatterers. At a concentration of 15 μg/ml, I(t) is slightly higher than in the control run, 
suggesting that at very high concentrations of P0, the number density of the calcium phosphate 
particles increases by a small amount. Overall, this peptide exhibits a very weak inhibitory effect 
on the growth of HA crystals. 
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Figure 4. 9: (A) Mean scattered light intensity as a function of time, (B) mean hydrodynamic radius as a 
function of time, (C) scattered light intensity as a function of hydrodynamic radius for different concentration 
of P0. 
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4.7 Dynamic Light Scattering Results for P3 
 
The inhibitory effect of P3, which is a synthetic peptide containing 3 phosphates corresponding 
to OPN sequence 220-235, was measured using dynamic light scattering. We added 0.3, 0.5, 1, 
2, and 5 μg/ml P3 to a calcium phosphate solution that contained 5.40 mM Ca2+ and 
3.37 mM PO4
3-
. The P3 concentrations correspond to approximately 0.15, 0.25, 0.50, 1.0, and 
2.50 μM, respectively. In contrast to P0, the inhibitory effect of P3 was observable at relatively 
low concentrations.  
As illustrated in Figure 4.10 (A), the presence of P3 causes the scattered intensity to drop, with 
the count rate becoming lower as the concentration of P3 increases. At the highest studied 
concentration of the peptide, 5 μg/ml, the mean scattered light intensity at the end of the 
measurement shows an approximate ten-fold reduction relative to the control experiment.  
The effect of P3 on   ̅ is presented in Figure 4.10 (B). It shows that increasing the concentration 
of P3 has no measurable effect on the hydrodynamic radius of HA crystals. For the highest 
concentration of P3, the hydrodynamic radius at the end of the experiment decreases by 4.7% 
relative to the control level. No delay in crystal growth was observed in the presence of P3.  
The scattered light intensity as a function of the hydrodynamic radius is shown in 
Figure 4.10 (C). As the figure illustrates, all concentrations of P3 reduce the photon count rate 
below the level of the control at any given hydrodynamic radius. The addition of increasing 
concentration of P3 resulted in decreased concentration of HA crystals. Altogether, P3 is a potent 
inhibitor of HA nucleation. 
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Figure 4. 10: (A) Mean scattered light intensity as a function of time, (B) mean hydrodynamic radius as a 
function of time, (C) scattered light intensity as a function of hydrodynamic radius for different 
concentrations of P3. 
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4.8 Dynamic Light Scattering Results for OPAR 
 
We also studied the effects of other OPN-derived synthetic peptides on HA growth. A peptide 
corresponding to the Osteopontin Poly-Aspartate Region (OPAR; OPN65-80) was incubated 
with a calcium phosphate solution containing 5.66 mM calcium and 3.53 mM phosphate ions.  
Figure 4.11 (A) shows the plot of the scattered photon count rate as a function of time in the 
presence of different concentrations of OPAR. The OPAR concentrations studied were 0.3, 0.5, 
1, 2, 5 and 7 μg/ml, corresponding to approximately 0.16, 0.3, 0.55, 1.1, 2.7, and 4.0 μM, 
respectively. Error bars are analogous to those in previous figures. The intensity of the scattered 
laser light starts to drop immediately and without any delay as we add OPAR to the calcium 
phosphate solution.    increases roughly linearly over the course of measurement and decreases 
as the OPAR concentration increases. With 7 μg/ml of OPAR added to the calcium phosphate 
solution, the intensity at the end of the measurement was decreased by a factor of six.  
Figure 4.11 (B) shows the mean hydrodynamic radius of the particles as well as the standard 
deviation of particle sizes. Regardless of the peptide concentrations, the HA crystals grow in a 
similar manner. At the beginning of the measurement, the sizes of the particles are more or less 
the same for all concentrations. It seems the particles are slightly smaller when OPAR is added, 
but the difference from the control is small. The fact that particles have sizes almost the same as 
the control solutions combined with their lower value for the scattered intensity, suggest that the 
concentration of the particles has decreased in the presence of OPAR. No delay in crystal growth 
is observed. These results suggest that the presence of OPAR significantly inhibits nucleation but 
not growth. Results for Im as a function of hydrodynamic radius are shown in Figure 4.11 (C). At 
small fixed sizes and in the presence of the lowest protein concentration, the particles scatter 
light as much as they do in the control experiment. As the concentration of OPAR increases, the 
photon count rates decreases. At about 300 nm size, the scattered intensity drops by about a 
factor of six for the highest OPAR concentration studied, 7 μg/ml. Since the addition of OPAR to 
the calcium phosphate solution decreases the concentration of the precipitant, these findings 
suggest that OPAR is a moderate inhibitor of nucleation. 
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Figure 4. 11: (A) Mean scattered light intensity as a function of time, (B) mean hydrodynamic radius as a 
function of time, (C) scattered light intensity as a function of hydrodynamic radius for different 
concentrations of OPAR. 
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4.9 Dynamic Light Scattering Results for pOPAR 
 
We also used DLS to measure the size and growth rate of crystals precipitating from a solution 
of calcium phosphate ions in the presence of the phosphorylated version of the osteopontin poly-
aspartate region (pOPAR). We added 0.3, 0.5, 1, and 2 μg/ml pOPAR to a calcium phosphate 
solution that contained 5.73 mM Ca
2+
 and 3.58 mM PO4
3-
. The pOPAR concentrations 
correspond to approximately 0.15, 0.26, 0.52, and 1.05 μM, respectively. 
The average scattered light intensity is plotted as a function of time for various concentrations of 
pOPAR in Figure 4.12 (A). The photon count rate is slightly lower than in the case of OPAR, 
however, the overall behaviour is almost the same. Increasing the concentration of pOPAR 
decreases the photon count relative to the control measurement.  
The effect of pOPAR on the hydrodynamic radius is presented in Figure 4.12 (B). It shows that 
the size of the particles in the presence of pOPAR is slightly smaller than in control over the 
course of measurement. At all studied pOPAR concentrations, the growth rates of the 
precipitating crystals are similar to each other and to the control. Furthermore, no delay in the 
growth of these calcium phosphate particles is observed. 
The effect of pOPAR concentration becomes more evident if the average scattered light intensity 
as a function of hydrodynamic radius is plotted. Figure 4.12 (C) illustrates that at a particular size 
of the scatterers,    decreases as the amount of the peptide is increased, meaning that the number 
density of the HA particles becomes lower as the pOPAR concentration is increased. In the 
presence of pOPAR, few particles form at early times but they grow at the same rate as in the 
control experiment. Fewer particles imply that pOPAR reduced the level of nucleation of HA. 
Since in the presence of pOPAR the crystals become slightly smaller, pOPAR may also have a 
small effect on the growth of the hydroxyapatite crystals. 
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Figure 4. 12: (A) Mean scattered light intensity as a function of time, (B) mean hydrodynamic radius as a 
function of time, (C) scattered light intensity as a function of hydrodynamic radius for different 
concentrations of pOPAR. 
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4.10 Dynamic Light Scattering Results for rBSP 
 
It has been proposed that BSP acts to initiate calcification in mineralized tissues [20,47]. To test 
this hypothesis, the effect of recombinant BSP on hydroxyapatite crystal formation was 
measured using dynamic light scattering. We attempted to find a concentration of calcium and 
phosphate ions at which precipitation of crystals does not happen in the absence of rBSP, but did 
happen in the presence of rBSP. It was postulated that BSP would cause the spontaneous 
nucleation of crystals below the normal threshold concentrations of calcium and phosphate ions. 
We studied the effect of adding protein on two solutions with different concentrations of calcium 
and phosphate. The first solution contained 5.20 mM Ca
2+
 and 3.25 mM PO4
3-
 and the second 
solution contained slightly higher calcium and phosphate ion concentrations: 5.40 mM Ca
2+
 and 
3.37 mM PO4
3-
.  
Figures 4.13 (A) and (B) show the scattered intensity and the hydrodynamic radius as a function 
of time for precipitation from the first solution for a control experiment and in the presence of 1, 
2, 4 and 6 µg/ml rBSP, corresponding to molar concentrations of approximately 0.03, 0.06, 0.12, 
and 0.18 μM rBSP. The scattered photon count rate is very low for this solution, indicating a low 
concentration of scatterers. As can be observed from Figure 4.13 (A), at an rBSP concentration 
of 1 µg/ml, the average scattered light intensity is above the level measured in the control 
experiment; at 2 µg/ml rBSP, the scattered intensity is initially lower but becomes equivalent to 
the control experiment at 40 minutes. At higher rBSP concentrations, Im is decreased throughout 
the 40 minute duration of the experiment. Figure 4.13 (B) shows that for all concentrations 
studied, the particles are smaller than in the control experiment. Increasing the concentration of 
rBSP decreases the size of the crystals at any given time. This suggests that rBSP at 1 and 
2 µg/ml enhance nucleation. 
As mentioned above, for a concentration of 1 µg/ml the scattered intensity is higher than the 
control value, but the hydrodynamic radius is smaller.    depends on both the size as well as the 
concentration of the scatterers. Since Im is higher than the control value for 1 µg/ml, while   ̅ is 
smaller we can infer that the concentration of the calcium phosphate particles has increased in 
the presence of low protein concentration. For concentrations of 4 and 6 µg/ml, few particles are 
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detected within the first 1500 seconds of the experiment, and then the particles that do form grow 
slowly over the duration of the measurement. At the end of the experiment there is about a four-
fold reduction in   ̅ for 2 µg/ml rBSP compared to the control, though the scattered intensity is 
equivalent. This indicates that the concentration of the particles is increased compared to the 
control at 40 minutes, suggesting that at low protein concentration rBSP enhances nucleation. 
 
 
Figure 4. 13: (A) The mean scattered intensity versus time, and (B) The mean hydrodynamic radius of the 
scatterers as a function of time, for experiments in which rBSP is added to the 5.20 mM calcium and 3.25 mM 
phosphate solution. 
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This experiment was done only once. The results may be affected by small uncertainties in 
concentration due to pipetting uncertainties. More trials would be needed to allow a definitive 
conclusion. Nonetheless, our data suggest that rBSP enhances nucleation at low concentrations, 
while it appears to inhibit growth at 2 µg/ml and higher. 
This experiment was repeated with the higher-concentration solution containing 5.40 mM Ca
2+
 
and 3.37 mM PO4
3-
. The measured scattered photon count rate and the size of the particles are 
shown in Figure 4.14 (A) and (B). Based on the control data, at these ion concentrations there is 
substantial crystal formation in the absence of protein. Experiments were performed with 1, 2, 4, 
6, and 8 μg/ml of rBSP added to the solution, corresponding to molar concentrations of 
approximately 0.03, 0.06, 0.12, 0.18, and 0.23 μM. 
Adding 1 μg/ml rBSP to the solution does not have a significant effect on the scattered light 
intensity. For higher concentrations, however,    decreases as the rBSP concentration increases. 
The scattered light intensity has almost the same value for the two highest concentrations 
studied. 
The effect of rBSP on calcium phosphate precipitation at supersaturated concentrations of 
calcium and phosphate is similar to that observed with the addition of OPN, though the inhibition 
is markedly less. At 1 μg/ml rBSP, there is little change in    compared to the control 
experiment, but at higher concentrations of rBSP,    decreases (Fig 4.14 (A)). At 8 µg/ml, rBSP 
reduces    by 50% whereas 8 µg/ml of nOPN (Figure 4.4 (A)) and 6 µg/ml of rOPN 
(Figure 4.6 (A)) reduces     by 90% or more. Increasing the concentration of rBSP appears to 
cause a short delay in the increase of the scattered intensity, but, again, this effect is much less 
than that observed with both isoforms of OPN. 
Similar to what is observed for nOPN, once the particles begin to grow, the hydrodynamic radius 
increases more quickly in the presence of the protein than in the control experiment. After 1000 
seconds, the precipitating particles are actually larger than in the control experiment. However, it 
is not clear that rBSP causes a true delay in nucleation, since particle formation is observed at 
early times for all concentrations of rBSP tested. In contrast, the data for nOPN showed a more 
distinct absence of particle formation at early times.  
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To better distinguish the effect of rBSP on the HA crystal concentration, the scattered light 
intensity is plotted as a function of mean hydrodynamic radius in Figure 4.14 (C). At small 
values of   ̅, for high concentration of rBSP    is higher in the presence of the protein 
suggesting that rBSP promotes the formation of small particles. For   ̅ greater than about 
300 nm, however, the scattered light intensity is lower in the control experiment, suggesting 
fewer particles of larger size in the presence of the protein. The  ̅  vs. time data show that these 
particles grow faster than in the control experiment. The scattered intensity initially decreases as 
rBSP concentration increases, then appears to increase again for the highest rBSP concentrations 
studied. This will be discussed further in the Chapter 5. 
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Figure 4. 14: (A) The mean scattered intensity versus time, (B) the mean hydrodynamic radius of the 
scatterers as a function of time, (C) the mean scattered intensity as a function of hydrodynamic radius for 
rBSP added to a solution containing 5.40 mM calcium and 3.37 mM Phosphate.
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Chapter 5: Discussion 
 
Dynamic light scattering is a well-established, versatile and non-invasive technique which can 
provide information about the size distribution of the scatterers and particle populations in real 
time. Dynamic light scattering has long been a powerful tool for studying a wide range of 
phenomena. It offers an alternative approach to the study of the protein-biomineral interactions. 
In the work described in this thesis, we have used DLS to investigate the kinetics of the 
nucleation and growth of crystals from a supersaturated solution of calcium and phosphate ions 
in the presence of bone-related proteins and synthetic peptides. Unlike the traditional methods 
described in sections 1.4.1 and 1.4.2, DLS permits us to monitor the initial stages of the 
nucleation process and determine the size and relative concentration of the growing crystals as a 
function of time. This allows an immediate assessment of the effect of proteins on mineralization 
and nucleation. 
BSP has been shown previously to act as a nucleator of HA crystallization [20,47]. We attempted 
to study this phenomenon using DLS, but found that studying nucleation is not as simple as 
studying inhibition. It was particularly difficult to find a threshold ion concentration at which 
adding BSP triggers the formation of HA. We attempted to find the critical point at which CaPO4 
will not precipitate in the absence of BSP, but at which addition of BSP will result in biomineral 
nucleation. We modified the experimental solution changing the concentrations of salts and 
buffers. Unfortunately, we were unable to find a concentration at which BSP unambiguously 
caused nucleation. Poly glutamic acid, which has also been shown to be a potent driver of 
nucleation [84], was also not observed to induce nucleation in this system. Because of this we 
decided to change our approach and did not focus on the nucleation effects of BSP below the 
threshold for HA formation, but rather studied inhibitory proteins and peptides above the 
nucleation threshold. 
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5.1 Osteopontin 
 
Our results show that both native and recombinant OPN inhibit the precipitation of calcium 
phosphate particles from solution. Native OPN delays the nucleation of particles and causes a 
significant decrease in particle concentration compared to the control experiment. However, the 
few calcium phosphate particles that do nucleate grow faster than in the control experiment. At 
the end of the measurement, the mean particle size is greater than 1 μm. The time at which  ̅  
starts to grow significantly increases linearly with the concentration of nOPN. In the presence of 
OPN, the scattered light intensity is significantly below that of the control experiment, indicating 
that the number density of scattering particles has decreased. We can therefore conclude that the 
presence of nOPN strongly prevents the formation of the particles. This could have occurred in 
two ways: the nOPN could inhibit the nucleation of calcium phosphate particles, or it could 
prevent small nucleated clusters from growing large enough to be observed by the DLS detector.  
In the presence of rOPN, both the scattered light intensity and the size of particles decrease. 
Moreover, the particles grow more slowly than in the absence of protein. In contrast to the case 
of nOPN, rOPN does not cause any noticeable delay in early precipitation. We can thus infer that 
rOPN does not have any effect on the nucleation of calcium phosphate particles but it slows their 
growth. 
In vitro studies have indicated that OPN and natural and synthetic OPN peptides are strong 
inhibitors of nucleation [23,24,38] and growth [39] of HA crystals. Although the mechanism by 
which mineral formation and growth are inhibited is poorly understood, other studies have 
shown that OPN also inhibits the formation of other biominerals, such as calcium carbonate [37] 
and calcium oxalate [41,42]. Hunter and co-workers [38] found that modification of OPN's 
glutamic acid and aspartic acid residues reduces its inhibitory potency [38]. Constant 
composition studies, which measured seeded crystal growth, indicate that aspartic acid is a more 
effective inhibitor than glutamic acid [38]. It has also been demonstrated that the inhibition of 
crystal formation and growth by OPN involves an interaction between the contiguous aspartic 
acid segment of OPN and an array of lattice ions on the surface of the HA crystal [43,50]. 
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Grohe et al. found that phosphate groups had a significant role in bringing the peptide close to 
the crystal surface. They simulated three forms of the same OPN peptide (P0, P1, P3), which 
have the same amino acid sequence but different numbers of phosphorylations, interacting with a 
calcium oxalate monohydrate (COM) crystal face. They suggested that the adsorption of acidic 
peptides to the {100} face of these biominerals is governed by electrostatics and is not dependent 
on the particular amino-acid sequence [30]. Another group performed simulations on 
phosphorylated OPN peptides in the presence of calcium oxalate, and also concluded that 
phosphate groups are involved in the inhibition of crystal growth [46]. Therefore, phosphate 
groups increase the electronegativity of OPN, causing a strong interaction with positively 
charged crystal face. 
Phosphorylation plays a key role in OPN's mineral-modulating activity, with phosphorylated 
OPN or its related peptides being much more inhibitory than the non-phosphorylated 
recombinant peptides [38,45,46]. 
More recently de Bruyn et al. applied dynamic light scattering to characterize the effects of 
proteins on mineral formation. To evaluate the effect of PTMs, three isoforms of OPN – nOPN, 
rOPN and phosphorylated rOPN (p-rOPN) – were examined. Their investigation showed that 
both nOPN and p-rOPN inhibit the nucleation of particles from supersaturated calcium 
phosphate solutions. On the other hand, rOPN, which lacks the phosphorylations of nOPN, acted 
as an inhibitor of HA growth but not the nucleation [75]. 
Although phosphorylation of OPN seems to be essential to its capability to prevent mineral 
growth, it is not clear whether phosphorylation at particular sites in the protein is needed. In this 
thesis, we addressed this issue by testing some OPN-derived peptides for their effect on HA 
formation and growth. There is some overlap with the work done by de Bruyn and co-workers 
[75], and in such cases our results are in good agreement with theirs. 
The growth rate of the precipitating crystals in the presence of nOPN and rOPN are plotted as a 
function of protein concentration in Figure 5.1. A straight line was fitted to the hydrodynamic 
radius data from each run at the time when the hydrodynamic radius was 200 nm. The growth 
rate increases with [nOPN], while rOPN causes it to decrease. The decrease in growth rate, 
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combined with the absence of a delay in precipitation, suggests that rOPN inhibits the growth, 
but not the nucleation of HA crystals. 
 
 
Figure 5. 1: Growth rate as a function of concentration for nOPN and rOPN at  
 ̅        . 
 
5.2 Quantitative Comparison of Peptides 
 
The experiments were performed on different days with slightly different concentrations. To 
compare the results obtained for the different OPN-related peptides, the data for the 
hydrodynamic radius of precipitating particles were normalized over time with respect to the 
control data. The control data were fitted to a cubic polynomial. Figure 5.2 (A) shows   ̅ data 
from a typical control run with the fitted polynomial. The deviations of the data from the fit are 
illustrated in Figure 5.2 (B). For normalization, the hydrodynamic radius from the peptide run is 
divided by the fitted value of   ̅ for the control at the same time. 
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Figure 5. 2: (A) Typical data for the hydrodynamic radius in a control run. The red line is a fit to a cubic 
polynomial. (B) The deviations of the data from the fit. 
 
To compare the inhibitory effects of OPN-related peptides, their hydrodynamic radius data were 
normalized as described, then averaged over time. 
Figures 5.3 (A) and (B) show the mean normalized hydrodynamic radius as a function of 
concentration for P0 and P3 respectively. At low concentrations, P0 has no discernible effect on 
the growth of the HA crystals, but the normalized hydrodynamic radius decreases in the presence 
of a high concentration of P0. 
Increasing the concentration of P3 decreases the hydrodynamic radius substantially. At a 
concentration of 5 μg/ml, P0 does not have a measurable effect on the mean normalized 
hydrodynamic radius over the forty-minute incubation, while the same concentration of P3 
results in a 15% decrease in the mean normalized hydrodynamic radius. This indicates that the 
three phosphate groups on P3 play a major role in the inhibition of HA growth. 
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Figure 5. 3: Mean normalized hydrodynamic radius as a function of concentration for A) P0 and B) P3. 
 
The growth rate of the precipitating crystals in the presence of P0 and P3 is plotted as a function 
of concentration in Figure 5.4. The growth rate was determined by fitting a straight line to the 
hydrodynamic radius data for each run at the time when the hydrodynamic radius was 200 nm. 
The growth rate for both peptides decreases with increasing concentration, but the effect is much 
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more pronounced for P3. This result also indicates that the three phosphates on the P3 peptide 
increase its inhibition potency relative to that of P0. 
 
 
Figure 5. 4: Growth rate as a function of concentration for P0 and P3 at  
 ̅        . 
 
The mean normalized hydrodynamic radius for OPAR and pOPAR are plotted versus 
concentration in Figures 5.5 (A) and (B) respectively. These two peptides, which differ only by 
the phosphate group on pOPAR, both moderately inhibit the growth of HA crystals at 
concentrations up to 2 μg/ml. At higher concentrations of OPAR, the mean value of the 
normalized hydrodynamic radius increases back to the control value. This behaviour is not 
understood but suggests that the inhibitory potency of OPAR is somehow neutralized at high 
concentrations. 
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Figure 5. 5: Mean normalized hydrodynamic radius as a function of concentration for A) OPAR and B) 
pOPAR. 
 
Figure 5.6 shows the same data for both peptides at low concentrations. Up to 2 μg/ml both 
peptides have roughly the same inhibitory effect on HA growth but the mean normalized 
hydrodynamic radius is slightly smaller for pOPAR. This suggests that the aspartic acid groups 
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in both peptides cause inhibition, but also that the extra phosphate on the pOPAR increases its 
inhibitory effect. 
 
 
Figure 5. 6: Mean normalized hydrodynamic radius as a function of concentration for OPAR and pOPAR. 
 
The growth rate as a function of concentration for OPAR and pOPAR is plotted in Figure 5.7. 
Both OPAR and pOPAR decrease the growth rate of HA crystals. At concentrations up to 
2 μg/ml the two peptides have approximately the same effect in reducing the growth rate, but the 
growth rate in the presence of pOPAR is consistently slightly lower. This result again suggests 
that the 11 aspartic acid residues in the two peptides prevent HA crystals from growing and that 
the additional phosphate in pOPAR increases its inhibition potency. 
The role of phosphate groups in the interaction between OPN-related peptides and biominerals 
has been studied using molecular dynamics (MD) simulations. These simulations have 
investigated the interaction of peptides with the surface of hydroxyapatite [39] as well as with 
calcium oxalate monohydrate (COM, CaC2O4.H2O) which is also found in kidney stones [30]. 
The OPN-related peptides we studied are negatively charged and are attracted to the Ca
2+
-rich 
{100} faces of HA and COM. More potent inhibitors are attracted more closely to the {100} 
faces of both HA and COM [30,39]. The simulations of Azzopardi et al. [39] and Grohe et al. 
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[30] suggested that the adsorption of acidic peptides to the {100} face of these biominerals is 
governed by electrostatics and is not dependent on the particular amino-acid sequence.  
 
 
Figure 5. 7: Growth rate as a function of concentration for OPAR and pOPAR P3 at  
 ̅        . 
 
The analysis of Azzopardi et al. suggested that the adsorption strength is inversely related to the 
isoelectric point, PI, of the peptide. The PI is the pH value at which the molecule carries no net 
electrical charge. Azzopardi et al. found in their simulations that the peptides which approached 
the {100} face of HA closely were those with the lowest PI. In other words, more inhibitory 
peptides have lower isoelectric points than less inhibitory peptides. They calculated PI for four 
virtual peptides: OPAR, pOPAR, P0, and P3, which is shown in Table 5.1.  
Azzopardi's simulations showed that pOPAR, which includes the poly aspartic acid sequence of 
OPN, formed the closest contact with the {100} face of HA. In addition to the aspartic acids, the 
single phosphoserine approached the {100} face most closely.  
Atomic scale molecular dynamics simulations performed by Grohe et al. found that the triply-
phosphorylated peptide P3, absorbed to the {100} crystal face of COM much more rapidly than 
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the singly-phosphorylated P1. They concluded that the phosphates on the phosphoserines drove 
the peptide close to the COM crystal face, leading to the more effective inhibition of crystal 
growth. Of interest, the authors noted that the acidic amino acid residues in P3 were found closer 
to the crystal face than the phosphates. 
The inhibition of HA growth by pOPAR, OPAR, P3 and P0 has also been studied by the constant 
composition seeded growth method by Azzopardi et al. [39]. Based on the effects of these 
peptides on the seeded growth of HA, they determined the concentration of a particular peptide 
needed to inhibit the crystal growth by half. This is referred to as the IC50 value. A larger IC50 
value is indicative of less inhibitory strength. Their results are summarized in Table 5.1 [39]. 
The work of Azzopardi et al. and Grohe et al. indicated that P0 has weak inhibitory activity. Our 
results on P0 are in good agreement with theirs [30,39]. Table 5.1 compares our DLS results with 
those of Azzopardi et al. Based on the DLS results, the order of the inhibitory effect on HA 
growth at 2 μg/ml peptide concentrations is pOPAR>OPAR>P3>P0. Measurements were not 
done on P0 at 2 μg/ml, but based on data at higher concentration its inhibitory effect is expected 
to be less than that of P3. Grohe's simulations established the order of inhibitory potency on 
COM crystals for the OPN-derived peptides that they studied to be P3>P1>P0. 
Table 5.1 indicates a small difference in the PI values of OPAR and pOPAR, which implies that 
both have similar inhibitory potency due to the presence of the aspartic acid residues. Our DLS 
results confirm that inhibitory potency increased with the addition of one phosphate group. We 
showed that OPAR prevents HA formation, while phosphorylation of OPAR in addition to 
inhibiting the nucleation of HA causes a decrease in crystal growth. This explanation is also true 
for P3. Having three extra phosphates enhanced the inhibitory potency of P3 over that of P0. 
Based on the constant composition (CC) seeded HA growth, IC50 value, and the calculated PI 
value, the order of inhibitory potency for the OPN-derived peptides to be 
P3>pOPAR>OPAR>P0. Although the position of P3 in this sequence is different in our results 
from in those of Azzopardi et al., both studies show that phosphorylations play a key role in 
inhibition potency of peptides. 
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Table 5. 1: Inhibitory potency of OPN peptides, adopted from [39] and DLS results. 
Peptide 
PI 
value 
IC50 
(μg/ml) 
(CC) 
Growth rate (nm/s) for 
2 μg/ml  inhibitors 
(DLS) 
Mean normalized hydrodynamic 
radius (nm) for 2 μg/ml inhibitors 
(DLS) 
P3 2.92 1.48 0.200 0.910 
pOPAR 3.39 1.93 0.180 0.840 
OPAR 3.60 2.97 0.186 0.870 
P0 4.17 >75 0.308 (at 5 µg/ml) 1.029 (at 5 µg/ml) 
 
The DLS and the constant-composition experiments are different, so it is difficult to compare 
them directly. In the DLS experiment, the composition of the solution varies as new crystals 
nucleate and grow, while in the constant-composition experiment the composition of the solution 
is kept fixed as pre-existing seed crystals grow. Although the constant-composition assay is not 
able to investigate nucleation or the early stages of crystal growth, the work of Azzopardi et al. 
indicates the inhibiting potency is more pronounced for the phosphorylated peptides, which is 
fully consistent with our DLS results. 
 
5.3 Bone sialoportein 
 
Based on previous observations [20,47], it was postulated that BSP would cause the spontaneous 
nucleation of crystals below the normal threshold concentrations of calcium and phosphate ions. 
We therefore studied the effect of adding rBSP to solutions with different concentrations of 
calcium and phosphate ions. 
First we tried to find a concentration of calcium and phosphate ions at which precipitation of 
crystals does not happen in the absence of rBSP, but did happen in the presence of rBSP. A 
solution of 5.20 mM Ca
2+
 and 3.25 mM PO4
3-
 was chosen. Since in this case the scattered light 
intensity is very low, the data are noisy. The count rate is quite small but did increase slightly 
over time, indicating that some crystals precipitated. Therefore, if indeed there is a threshold for 
the precipitation of particles, the chosen ion concentrations are still slightly above it. The second 
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solution contained higher calcium and phosphate ion concentrations, 5.40 mM Ca
2+
 and 
3.37 mM PO4
3-
, and significant precipitation did occur in the absence of rBSP. 
For the first case, our DLS results suggested that rBSP may enhance nucleation at very low 
concentrations, but appears to inhibit growth at concentrations higher than 2 µg/ml. 
For the second solution, the results show a delay in the increase of  ̅  for protein concentrations 
exceeding 1 μg/ml. Unlike the case of lower ion concentration, here the presence of rBSP delays 
the nucleation of the particles, and the delay time becomes larger as the concentration increases. 
The observed behaviour of rBSP in the solution with higher ion concentrations is similar to that 
observed for OPN in this work, and for p-rOPN in [75]. However, this inhibitory effect is less 
significant than that observed with OPN. Furthermore, our data at the higher ion concentrations 
suggest that there are more small particles in the presence of the protein than in the control 
experiment, suggesting that rBSP promotes the nucleation of HA crystals. It is of interest that 
with both rBSP and nOPN, the growth rate of the HA crystals is enhanced. It is postulated that 
since BSP and OPN have a high affinity for HA crystals, they will gradually be removed from 
the solution as the crystals form. Once this happens, the few crystals can grow at a faster rate 
than that seen in control solutions because of the increased availability of calcium and phosphate 
ions to drive growth [75]. 
Previous studies [20,47] have shown that BSP nucleates HA formation in agarose gel and solid-
phase collagen. Nucleation of HA precipitation by BSP was first observed in steady-state agarose 
gel experiments in 1993 [20]. Hunter and Goldberg observed the formation of HA in a gel 
containing BSP under conditions of sub-threshold calcium and phosphate saturation. Their 
studies suggested that the glutamic acid-rich sequences of BSP played a key role in the 
nucleation of HA crystals [20]. The chemical nature of the BSP-collagen interaction was 
investigated by Baht et al. in 2008 [47]. It was found that hydrophobic interactions were 
responsible for the binding of BSP to collagen and, based on previous studies [61], electrostatic 
forces appear to stabilize the interaction. In contrast, other proteins, such as dentin 
phosphophoryn and dentin matrix protein-1, bind to collagen electrostatically [47]. The acidic 
amino-acid-rich regions of these proteins are involved in collagen binding. It has been shown 
that the nucleation potency of BSP increases 10-fold when it is incubated in collagen as 
compared to agarose [47].  
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Hunter et al. in 1996 reported that in solution studies, BSP at concentrations up to 10 μg/ml had 
no effect on hydroxyapatite formation [22]. BSP and its peptides were shown to have an 
inhibitory effect of on crystal growth by Stubbs et al. [68]. In their system, which used a seeded 
HA crystal assay, native BSP and one of its major fragments were able to suppress crystal 
growth. They found that recombinant BSP could also block the growth of HA seeded crystals 
suspended in supersaturated solution of calcium and phosphate, but was not as potent as the 
native protein. This suggests that post translational modifications contribute to the ability of BSP 
to inhibit crystal growth [68].  
Goldberg et al. in 1996 suggested that although PTMs are not necessary for nucleation of BSP, 
lack of these modifications decrease the potency of the protein [58]. Tye et al. in 2003 compared 
the nucleating activity of nBSP and rBSP. Their results were in good agreement with those of 
Goldberg et al., and showed that the nucleation activity of BSP resides in two glutamic acid 
domains [50]. 
Molecular dynamics simulations on BSP-derived peptides suggest that the particular sequence of 
amino acids is not the only factor that determines the nucleation potency of the peptide, but that 
the peptide structure is also important [65]. 
The effect of dentin phosphophoryn (DPP) on hydroxyapatite formation and growth has been 
studied in an in vitro gelatin gel diffusion system [85]. At high concentrations of DPP 
(100 μg/ml), the de novo formation of HA decreases, while low concentrations of protein (0.010-
1 μg/ml) promoted de novo hydroxyapatite formation. These data suggest that DPP has a 
multifunctional role in the mineralization process [85]. DPP attached to agarose beads or 
collagen has also been shown to promote HA formation [86-89]. Thus it appears the formation of 
HA is promoted by immobilized DPP and hindered by high concentrations of DPP in solution. 
This appears to be similar to the behavior we observed for BSP, although more experimental 
work is needed to confirm this. 
Our results in general agree with the previously published studies on BSP and HA formation, 
although nucleation potency was not readily apparent by DLS. Additional effort is required to 
develop the most appropriate protocol for studying mineral nucleation. However, it is also 
possible that BSP does not nucleate well or at all in solution. The previously published studies 
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showing BSP-mediated nucleation of hydroxyapatite were done in steady-state agarose or 
collagen-gel systems, suggesting that confinement or constraints on the protein conformation 
may play a role.  
There is good evidence in the literature to support BSP-mediated inhibition of crystal growth. 
Our results are also in general agreement with this. Overall, the scattered intensity due to 
precipitating calcium phosphate is decreased by the addition of BSP, and while some crystals do 
become large, it appears that the majority do not. It would be of interest to determine if further 
addition of BSP, for example 20 minutes into a run, would affect the growth of these crystals. 
Overall, it seems that the behaviour of BSP is more complicated than the other proteins. We did 
not observe unambiguous nucleation under the experimental conditions we investigated. 
However there do seem to be similarities between our observations for BSP and what others 
have seen for DPP [85]. Many questions remain and substantial additional studies are needed to 
clarify the behaviour of BSP. 
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Chapter 6: Conclusions and Future Work 
 
6.1 Conclusions 
 
Improved understanding of the effect of modulatory proteins on the crystallization of 
hydroxyapatite could eventually lead to the development of drugs or bone repair therapies to 
control pathological calcifications resulting from the breakdown of the body’s natural 
biomineralization regulatory system. 
Dynamic light scattering has proven to be a versatile and convenient method to monitor the 
formation process of HA. DLS data provide information about the size distribution of the HA 
crystals and their concentrations in aqueous solutions that is not available from other techniques. 
This technique allows us to distinguish the effects of proteins and peptides on nucleation and 
growth separately. DLS provides an alternative approach to constant composition and steady 
state assays for examining the effects of bone-related proteins or synthetic peptides on the 
in vitro formation of HA. 
We used DLS to measure the time evolution of the particle size distribution and average 
scattered light intensity of HA crystals in the presence of proteins and peptides at particular ionic 
concentration and pH conditions.  
We found that native OPN inhibits the nucleation of HA crystals, while the non-phosphorylated 
rOPN strongly inhibits their growth. This confirms that phosphorylation of OPN is critical for 
the inhibition of nucleation, while the acidic amino acid groups alone can inhibit crystal growth. 
We also studied the inhibitory effects of some synthetic OPN-related peptides. Our results show 
that P0 exhibits a very weak inhibitory effect on the growth of HA crystals, while P3, with three 
phosphate groups added to the same amino acid sequence, is a potent inhibitor of HA nucleation. 
The peptide OPAR is found to moderately inhibit nucleation. On the other hand, the 
phosphorylated version of OPAR not only reduced the number of calcium-phosphate particles 
but also slightly slowed their growth. Overall, we found the order of inhibitory potency of the 
four OPN-derived peptides to be pOPAR>OPAR>P3>P0. 
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Our results for rBSP showed that for sub-threshold concentrations of calcium and phosphate it 
appears to function as a nucleator at lower protein concentrations, and very likely as an inhibitor 
of crystal growth at higher concentrations of protein.  
 
6.2 Future Work 
 
We tried to investigate the nucleation potency of BSP using DLS, but had little success. 
Additional effort is required to find the appropriate working concentrations of calcium and 
phosphate for studying the nucleation process and the question of whether BSP enhances 
mineralization from a solution. Additional study is also needed to determine whether the action 
of BSP is different in solution than it is in a gel, and if so, to understand the reasons for the 
difference. 
Since acidic proteins become nucleators of HA when immobilized, it would be intriguing to 
attempt DLS experiments using BSP and OPN covalently linked to agarose beads.  
If a protocol for a DLS-based nucleation assay can be established, DLS could be used to 
investigate the effects of BSP-derived peptides, the roles of PTMs in BSP, the effects of altering 
the poly-Glu sequences of BSP, and the effects of other protein modulators of biominerals. 
Our investigations have shown that several proteins and peptides are effective in inhibiting HA 
nucleation or growth. It would be of interest to analyze the effect of mixtures of different 
inhibitors using DLS. 
It would be useful to characterize the morphology of the crystal structures and precipitant at 
different stages of growth using XRD. Stopping crystal formation at early times and analyzing 
the crystals with XRD would provide insight in to the nature of the precipitating particles and the 
process by which HA crystals form in these solutions [70]. 
All of our DLS experiments to date have been performed at room temperature. Since the 
solubility of the calcium phosphate decreases as the temperature is lowered, performing DLS 
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experiments at physiological temperature would be a good idea. In addition, experiments as a 
function of temperature may provide an alternate way to investigate nucleation and inhibition.
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Appendix 
 
The twenty essential amino acids. The residues are shown in uncharged state. The three-letter 
and one-letter abbreviations are given below the chemical structure of each amino acid [91]. 
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